ENvue Medical Inc

ENvue Medical Inc(FEED)股票分析

$4.110

-0.191 (-4.64%)收盘时

Loading chart…
High
4.270
Open
4.260
VWAP
4.14
Vol
28.30K
Mkt Cap
Low
4.049
Amount
117.24K
EV/EBITDA, TTM
0.00

ENvue Medical, Inc. is a medical technology company advancing both non-invasive and minimally invasive solutions across clinical and home care settings. Its segments include NanoVibronix, ENvue and Corporate. NanoVibronix is engaged in selling its products directly to patients as well as through distributor agreements. ENvue is engaged in selling its systems and Nasoenteral tubes and related services. The Company focuses on two distinct technology platforms: Acoustic-based therapeutic technologies, including PainShield and UroShield, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms. The ENvue Navigation Platform, which is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract.

envuemed.com

AI analysis of ENvue Medical Inc (FEED)

sell

ENvue Medical, Inc. is not a good buy right now due to its significantly low price and poor financial performance. The current price is $0.34, and the stock has experienced a year-to-date change of -85.94%. Additionally, the RSI is at 23.926, indicating that the stock is oversold, but this could signal further downside risk rather than a buying opportunity. The company also reported a staggering net income loss of -22,621,000 USD in the most recent quarter, which raises concerns about its financial health.

估值指标

The current forward P/E ratio for ENvue Medical Inc (FEED) is 0.00, compared to its 5-year average forward P/E of -0.00.

Forward P/E

Strongly Overvalued
5Y Average P/E
-0.00
Current P/E
0.00
高估
-0.00
低估
-0.00

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
高估
0.00
低估
0.00

Forward P/S

Strongly Undervalued
5Y Average P/S
0.88
Current P/S
0.00
高估
1.04
低估
0.72

事件时间线

2026-08-10 (ET)

16:30:00

ENvue Medical Files $50M Mixed Securities Shelf

2026-08-04 (ET)

10:00:00

ENvue Medical Completes NanoVibronix Manufacturing Move to the U.S.

2026-07-15 (ET)

08:30:00

ENvue Medical Appoints Zeev Rotstein as Chairman of the Board

2026-05-18 (ET)

17:20:00

ENvue Medical Files to Sell 6M Shares of Common Stock

2026-05-12 (ET)

09:20:00

ENvue Medical Renews Three-Year Contract with Nonprofit Health System

资讯

FEED FAQ — answered by Alphio AI

ENvue Medical, Inc. is a medical technology company advancing both non-invasive and minimally invasive solutions across clinical and home care settings. Its segments include NanoVibronix, ENvue and Corporate. NanoVibronix is engaged in selling its products directly to patients as well as through distributor agreements. ENvue is engaged in selling its systems and Nasoenteral tubes and related services. The Company focuses on two distinct technology platforms: Acoustic-based therapeutic technologies, including PainShield and UroShield, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms. The ENvue Navigation Platform, which is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. It operates in the Healthcare sector.

ENvue Medical, Inc. is not a good buy right now due to its significantly low price and poor financial performance. The current price is $0.34, and the stock has experienced a year-to-date change of -85.94%. Additionally, the RSI is at 23.926, indicating that the stock is oversold, but this could signal further downside risk rather than a buying opportunity. The company also reported a staggering net income loss of -22,621,000 USD in the most recent quarter, which raises concerns about its financial health.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始